Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J McGough

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Biological Psychiatry|June 14, 2005
Attention-deficit/hyperactivity disorder pharmacogenomicsJames J McGough
Current Opinion in Investigational Drugs (London, England : 2000)|September 5, 2002
MethyPatch NovenNatasha Sane, James J McGough
Child and Adolescent Psychiatric Clinics of North America|February 26, 2008
The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapyMark A Stein, James J McGough
The American Journal of Psychiatry|October 30, 2004
Diagnostic controversies in adult attention deficit hyperactivity disorderJames J McGough, Russell A Barkley
Psychiatry (Edgmont (Pa. : Township))|December 17, 2009
Estimating the size of treatment effects: moving beyond p valuesJames J McGough, Stephen V Faraone
Expert Opinion on Emerging Drugs|July 2, 2005
New drugs for treatment of attention-deficit/hyperactivity disorderBowen Chung, Alejandra R Suzuki, James J McGough
Expert Review of Neurotherapeutics|July 20, 2005
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorderJames J McGough, Caroly S Pataki, Robert Suddath
Expert Opinion on Emerging Drugs|December 2, 2004
New drugs for the treatment of attention-deficit/hyperactivity disorderCaroly S Pataki, David T Feinberg, James J McGough
CNS Drugs|January 22, 2010
Progress and promise of attention-deficit hyperactivity disorder pharmacogeneticsTanya E Froehlich, James J McGough, Mark A Stein
Journal of Child and Adolescent Psychopharmacology|June 13, 2009
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderFloyd R Sallee, Andrew Lyne, Timothy Wigal, et al.
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Biological Psychiatry|June 14, 2005
Attention-deficit/hyperactivity disorder pharmacogenomicsJames J McGough
Current Opinion in Investigational Drugs (London, England : 2000)|September 5, 2002
MethyPatch NovenNatasha Sane, James J McGough
Child and Adolescent Psychiatric Clinics of North America|February 26, 2008
The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapyMark A Stein, James J McGough
The American Journal of Psychiatry|October 30, 2004
Diagnostic controversies in adult attention deficit hyperactivity disorderJames J McGough, Russell A Barkley
Psychiatry (Edgmont (Pa. : Township))|December 17, 2009
Estimating the size of treatment effects: moving beyond p valuesJames J McGough, Stephen V Faraone
Expert Opinion on Emerging Drugs|July 2, 2005
New drugs for treatment of attention-deficit/hyperactivity disorderBowen Chung, Alejandra R Suzuki, James J McGough
Expert Review of Neurotherapeutics|July 20, 2005
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorderJames J McGough, Caroly S Pataki, Robert Suddath
Expert Opinion on Emerging Drugs|December 2, 2004
New drugs for the treatment of attention-deficit/hyperactivity disorderCaroly S Pataki, David T Feinberg, James J McGough
CNS Drugs|January 22, 2010
Progress and promise of attention-deficit hyperactivity disorder pharmacogeneticsTanya E Froehlich, James J McGough, Mark A Stein
Journal of Child and Adolescent Psychopharmacology|June 13, 2009
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderFloyd R Sallee, Andrew Lyne, Timothy Wigal, et al.
Pageof 10